Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain.
Int J Mol Sci. 2022 Aug 22;23(16):9479. doi: 10.3390/ijms23169479.
The interleukin-1 (IL-1) family is involved in the correct functioning and regulation of the innate immune system, linking innate and adaptative immune responses. This complex family is composed by several cytokines, receptors, and co-receptors, all working in a balanced way to maintain homeostasis. Dysregulation of these processes results in tissue inflammation and is involved in the pathogenesis of common inflammatory dermatoses such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. Therefore, therapeutic targeting of IL-1 pathways has been studied, and several monoclonal antibodies are currently being assessed in clinical trials. So far, promising results have been obtained with anti-IL-36R spesolimab and imsidolimab in pustular psoriasis, and their efficacy is being tested in other conditions.
白细胞介素-1（IL-1）家族参与固有免疫系统的正常功能和调节，将固有免疫和适应性免疫反应联系起来。这个复杂的家族由几种细胞因子、受体和共受体组成，它们协同作用以维持体内平衡。这些过程的失调会导致组织炎症，并参与常见炎症性皮肤病如银屑病、化脓性汗腺炎和特应性皮炎的发病机制。因此，已经研究了针对白细胞介素-1途径的治疗靶向，目前正在临床试验中评估几种单克隆抗体。迄今为止，抗白细胞介素-36R 特异性单克隆抗体 spesolimab 和 imsidolimab 在脓疱性银屑病中取得了有前景的结果，其疗效正在其他情况下进行测试。
